Also known as: LOXO-292, Retevmo
Selpercatinib is marketed as RETEVMO, a selective RET-targeted kinase inhibitor indicated across RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, RET fusion-positive thyroid cancer, and other RET fusion-positive solid tumors. Labeling includes both adult and pediatric indications for patients aged 2 years and older in several settings. U.S. initial approval was in 2020.
Eli Lilly's Retevmo met the primary endpoint in a Phase III lung cancer trial, Merck discontinued its TROP2 ADC MK-6837, and a Tango/Revolution combination showed benefit in pancreatic cancer.
An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Eli Lilly is preparing for the launch of oral weight loss pill Orforglipron with a US$3 billion, decade-long investment in China, while advancing its oncology and genetic medicine pipeline with positive Phase 3 results for Retevmo and a milestone in CRISPR collaboration.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
Phase 3 LIBRETTO-432 trial met its primary endpoint, showing selpercatinib delivered statistically significant and clinically meaningful improvement in event-free survival versus placebo as adjuvant therapy in early-stage RET fusion-positive NSCLC.
Eli Lilly has stockpiled $1.5 billion in inventory for Orforglipron ahead of an expected FDA decision in April. The oral weight-loss pill aims to compete with Novo Nordisk's recently approved oral Wegovy.
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
Eli Lilly's Retevmo demonstrated statistically significant improvement in event-free survival versus placebo in stage II-IIIA RET fusion-positive non-small cell lung cancer following curative therapy in the phase 3 LIBRETTO-432 trial.
Eli Lilly announced positive Phase 3 LIBRETTO-432 trial results showing Retevmo (selpercatinib) significantly improved event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer as adjuvant therapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07543887 |
Selpercatinib and Body Composition |
COMPLETED | |
| NCT07146893 |
Feasibility Study for Repurposing RET Inhibitors |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07010393 |
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT06532149 |
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
RECRUITING | |
| NCT05906836 |
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05668962 |
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC |
RECRUITING | PHASE2 |
| NCT05630287 |
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants |
COMPLETED | PHASE1 |
| NCT05630274 |
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05469113 |
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05469100 |
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function |
COMPLETED | PHASE1 |
